Right now, both are “associated with recurrent abdominal pain and are among the most commonly diagnosed medical problems in pediatrics,” says Therapy. To treat it, many companies – and physicians will ...

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science ...

Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% ...

Shares of NeurAxis, Inc. NRXS have gained 41.2% since it reported earnings for the quarter ended Sept. 30, 2024. This strong performance contrasts with the S&P 500 index, which saw a decline of 0.9% ...

Zacks Investment Research has recently initiated coverage of NeurAxis, Inc. NRXS, assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook for the ...

. Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the“Company”) (NYSE American: ...

Despite experiencing an operating loss, Neuraxis remains optimistic about its future growth, supported by new FDA indications and strategic initiatives. Additionally, Neuraxis entered into an At The ...

CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that ...

With so many metal bands today adopting the weak technique over substance arrangement style usually reserved for the prog-rock scene, it's refreshing to find a group who can pull off amazing skills ...

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...